Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction

European Journal of Surgical Oncology

Volumn 32, Issue 10, 2006, Pages 1114-1118

  Forshaw, M J ^a   Gossage, J A ^a   Chrystal, K ^a   Cheong, K ^a   Atkinson, S ^a   Botha, A ^a   Harper, P G ^a   Mason, R C ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Neoadjuvant chemotherapy; Oesophageal neoplasms; Response evaluation

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTER INFECTION; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; FEMALE; GASTRECTOMY; HAND FOOT SYNDROME; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERFORATION; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SEPTICEMIA; STAPHYLOCOCCUS INFECTION; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT INFECTION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 33751177126     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.02.025     Document Type: Article

References (28)

1. Hofstetter W., Swisher S.G., Correa A.M., et al. Treatment outcomes of resected esophageal cancer. Ann Surg 236 (2002) 376-385
2. Lerut T., Coosemans W., De Leyn P., Van Raemdonck D., Deneffe G., and Decker G. Treatment of esophageal carcinoma. Chest 116 (1999) 463S-465S
3. O'Sullivan G.C., Sheehan D., Clarke A., et al. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 116 (1999) 543-548
4. Kaklamanos I.G., Walker G.R., Ferry K., Franceschi D., and Livingstone A.S. Neoadjuvant treatment for respectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomised clinical trials. Ann Surg Oncol 10 (2003) 754-761
5. Lordick F., Stein H.J., Peschel C., and Siewert J.R. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91 (2004) 540-551
6. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without neoadjuvant chemotherapy in oesophageal cancer: a randomised control trial. Lancet 359 (2002) 1727-1733
7. Highley M.S., Parnis F.X., Trotter G.A., et al. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. Br J Surg 81 (1994) 1763-1765
8. Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1997) 261-267
9. Andreyev H.J.N., Norman A.R., Cunningham D., et al. Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). Eur J Cancer 31A (1995) 2209-2214
10. Bamias A., Hill M.E., Cunningham D., et al. Epirubicin, Cisplatin and protracted venous infusion of 5-Fluorouracil for esophagogastric adenocarcinoma. Cancer 77 (1996) 1978-1985
11. Geh J.I., Glynne-Jones R., Kwok Q.S.K., et al. Preoperative ECF chemotherapy in Gastro-oesophageal adenocarcinoma. Clin Oncol 12 (2000) 182-187
12. Melcher A.A., Mort D., and Maughan T.S. Epirubicin, Cisplatin and continuous infusion 5-Fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Cancer 74 (1996) 1651-1654
13. Cunningham D., Allum W.H., Stenning S.P., Weeden S., and for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer. Final results of a randomised controlled trial (the MAGIC trial ISRCTN 93793971). ASCO abstracts (2005) 4001 (abstract)
14. In: Sobin L.H., and Wittekind C.H. (Eds). TNM classification of malignant tumours. 5th ed. (1997), Wiley-Liss, New York
15. World Health Organisation. WHO handbook for reporting results of cancer treatment (publication no. 48) (1979), WHO, Geneva
16. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
17. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Archer V.R., Mulholland P.J., Stocken D.D., Darnton S.J., and Ferry D.R. Combined results from three Phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 13 (2001) 164-169
19. Alderson D. Neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 13 (2001) 153-154
20. Lerut T., Coosemans W., Decker G., De Leyn P., Nafteux P., and Van Raemdonck D. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol 10 (2001) 113-122
21. Forshaw M., Stephens J., Gossage J., et al. Surgical outcomes of oesophagogastrectomy: does neo-adjuvant therapy increase the risk? A retrospective audit. Br J Surg 91 Suppl. 1 (2004) 141
22. McCulloch P., Ward J., Tekkis P.P., ASCOT group of surgeons, and British Oesophago-Gastric Cancer Group. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ 327 (2003) 1192-1197
23. Allum W.H., Griffin S.M., Watson A., Colin-Jones D., Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, British Society of Gastroenterology, and British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut 50 Suppl. 5 (2002) v1-v23
24. Ancona E., Ruol A., Santi S., et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with respectable esophageal squamous cell carcinoma. Cancer 91 (2001) 2165-2174
25. Brucher B.L., Stein H.J., Zimmermann F., et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 30 (2004) 963-971
26. Walsh T.N., Grannell M., and Mansoor S. Predictive factors for success of neoadjuvant therapy in upper gastro-intestinal cancer. J Gastroenterol Hepatol 17 (2002) S172-S175
27. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
28. Kostakoglu L., and Goldsmith S.J. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 45 (2004) 56-68